『您的瀏覽器不支援JavaScript功能,若網頁功能無法正常使用時,請開啟瀏覽器JavaScript狀態』

跳到主要內容區塊

工業技術研究院

:::

技術名稱: 抗人類表皮生長因子受體抗體及其應用

技術簡介

人類表皮生長因子受體(EGFR)已被視為是有效的目標物用於發展抗腫瘤治療。可表現EGFR之32D(32D-EGFR)細胞株已被報導可用於EGFR相關訊息傳遞路徑的抑制劑篩選。利用32D-EGFR細胞與重組之EGFR細胞外區域(EGFR-ECD)自單域抗體庫中針對EGFR進行噬菌體展示篩選。利用此合併篩選策略成功篩選出一個新穎抗人類EGFR抗體。利用人類抗體Fc片段融合單域抗體使其成為二價抗體形態並利用EGFR過量表現的A431細胞測定出其結合強度為~52 nM。同時也利用A431細胞進行細胞內噬作用與抑制細胞生長能力分析。綜合上述結果,利用合併32D-EGFR細胞與重組之EGFR細胞外區域(EGFR-ECD)針對EGFR進行噬菌體展示篩選為有效率策略,因為不需要額外免疫動物用以產生抗體庫。

Abstract

Epidermal growth factor receptor (ErbB1, EGFR) has been considered as a valid target for development anti-cancer targeted therapies. The EGFR-transfected 32D (non-tumorigenic murine hematopoetic cells) (32D-EGFR) cell line has been reported as a suitable EGFR pathway inhibitor screening system. Domain antibodies (dAbs) specific for EGFR have been directly isolated via panning a phage display human domain antibody library on 32D-EGFR and recombinant extracellular domain of EGFR (EGFR-ECD). One novel human EGFR specific domain antibody was isolated from this combinative screening strategy. A recombinant dimeric form of dAb, dAb-hFc, has been constructed by fusing dAb to the fragment crystallizable region (Fc) of human IgG1. The KD value of dAb-hFc was ~52 nM as determined on EGFR-overexpressing A431 cells. Internalized and growth inhibition activity of dAb -hFc were also confirmed as determined on A431 cells. Taken together, phage display screening of EGFR specific antibody based on combination of 32D-EGFR cell and EGFR-ECD is an efficient strategy without additional animal immunization to construct antibody library.

技術規格

1.為全人源抗體序列。 2.該抗體具有與人類表皮生長因子受體專一性結合的能力。 3.抗體可藉由一受體媒介內噬作用進入細胞中。 4.兩價單域抗體與人類表皮生長因子受體結合強度落於52 nM左右。

Technical Specification

1.Fully human antibody sequence. 2.The anti-human EGFR antibody is capable of specifically binding to a human EGFR. 3.The anti-human EGFR antibody is capable of entering a cell through receptor-mediated endocytosis. 4.The equilibrium constant (KD) values of dimeric form antibody to human EGFR is ~ 52 nM.

技術特色

利用小鼠32D(有無EGFR表現)細胞與嗜菌體展示(phage display)技術在人類單域抗體庫(domain antibody library)內進行針對人類表皮生長因子受體(EGFR)抗體篩選。經過序列分析比對證實dAb-D2單域抗體其變異區(variable region)為未曾被報導過的新穎序列。利用EGFR過量表現之人類A431細胞進行抗體相關之活性分析,dAb-D2-hFc重組抗體與A431細胞具有高度親和性(結合強度落於nanomolar range)並同時具有細胞內噬作用之能力(internalized activity),細胞生長抑制實驗也證實dAb-D2-hFc重組抗體可抑制A431細胞生長。dAb-D2-hFc重組抗體對於EGFR具有高度親和性與抑制細胞生長能力可應用於標靶傳遞藥物(targeted drug delivery)或抑制腫瘤細胞生長。

應用範圍

可應用於生物醫學相關市場,如診斷試劑開發、治療用抗體開發等領域。

接受技術者具備基礎建議(設備)

1.哺乳類細胞培養設備。 2.蛋白質純化設備。

接受技術者具備基礎建議(專業)

1.分子生物學。 2.哺乳類細胞培養技術。 3.蛋白質純化技術。

技術分類 生物工程

聯絡資訊

聯絡人:王翔靖 標靶藥物技術中心

電話:+886-3-5912149 或 Email:RickHCWang@itri.org.tw

客服專線:+886-800-45-8899

傳真:+886-3-5910097

[{"text":"企業網","weight":13.0},{"text":"材化所","weight":11.5},{"text":"機械所","weight":10.0},{"text":"綠能所","weight":9.4},{"text":"生醫所","weight":8.0},{"text":"半導體","weight":6.2},{"text":"南分院","weight":5.0},{"text":"太陽能","weight":5.0},{"text":"課程","weight":5.0},{"text":"遠紅外線","weight":5.0},{"text":"雷射","weight":4.0},{"text":"LED","weight":4.0},{"text":"LED可見光","weight":3.0},{"text":"5G","weight":3.0},{"text":"工研人","weight":3.0},{"text":"電光所","weight":3.0},{"text":"綠能與環境研究所","weight":3.0},{"text":"機械","weight":3.0},{"text":"資通所","weight":2.0},{"text":"面板","weight":2.0},{"text":"文字轉語音","weight":2.0},{"text":"實習","weight":2.0},{"text":"無人機","weight":2.0},{"text":"生醫","weight":2.0},{"text":"3D","weight":2.0},{"text":"v2x","weight":2.0},{"text":"員工","weight":2.0},{"text":"地圖","weight":2.0},{"text":"太陽光電","weight":2.0},{"text":"材料與化工研究所","weight":1.0}]